article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin.

Insulin 328
article thumbnail

FDA rejects Provention’s type 1 diabetes drug teplizumab

pharmaphorum

Three months ago, the FDA said it was unconvinced by a bridging study designed to show equivalence between Provention’s product intended for commercial sale, made by contract manufacturer AGC Biologics, and the drug that teplizumab’s original developer Eli Lilly used in clinical trials.

Drugs 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Decline of novel drug approvals means less business for cutting-edge CMOs

Pharmaceutical Technology

This is mixed news for contract manufacturing organisations (CMOs), as large CMOs such as Thermo Fisher Scientific (Waltham, MA, US) and Catalent Inc (Somerset, NJ, US) are typically involved in the manufacture of the most innovative products. The drug increases insulin synthesis and release.

Drugs 130
article thumbnail

FDA sets August decision date for Provention’s type 1 diabetes drug

pharmaphorum

Provention has modified its 14-day treatment course with teplizumab to match the exposure to the drug that was seen with the clinical trial material, and has also submitted responses to FDA questions about manufacturing and product quality.

Drugs 52
article thumbnail

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

pharmaphorum

” T1D occurs when the immune system attacks and destroys the insulin-producing pancreatic beta cells that make insulin, and occurs in three stages. In stage 1 there are antibodies against the beta calls, but blood glucose levels remain normal and there are no symptoms.

Drugs 52
article thumbnail

Sartorius Stedim Biotech to acquire Novasep’s chromatography process equipment division

The Pharma Data

Novasep’s division expects to generate sales revenue of approximately 37 million euros in 2020 at double-digit profit margins and employs approximately 100 people, the majority of whom work at its Pompey site in northern France and some in the USA , China and India. 6,200 people, and earned sales revenue of 1,440.6 million euros.

article thumbnail

Sartorius to acquire Novasep’s chromatography process equipment division

The Pharma Data

Novasep’s division expects to generate sales revenue of approximately 37 million euros in 2020 at double-digit profit margins and employs approximately 100 people, the majority of whom work at its Pompey site in northern France and some in the USA , China and India. In fiscal 2019, the company earned sales revenue of some 1.83